GV20 Therapeutics

GV20 Therapeutics will present updated Phase 1 data on GV20-0251, the first AI-designed antibody targeting the novel immune checkpoint IGSF8, at ASCO 2025.

GV20 Therapeutics has formed a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation to develop first-in-class antibody-drug conjugates targeting novel tumor antigens.

GV20 Therapeutics presented Phase 1 data for GV20-0251, marking the first clinical results for an AI-designed antibody targeting an AI-predicted immune checkpoint IGSF8.